Engineering Metal‐Organic‐Framework‐Based STING Nanoagonists for PROTAC‐Enhanced Cancer Chemo‐Metalloimmunotherapy
Advanced Science · 2026-01 · 13 (2)
DOI: 10.1002/advs.202515006 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 13.10.2025. Verfasst von Zhenzhen Chen und 3 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Analytical Chemistry for Life Science, School of Chemistry and Chemical Engineering, Chemistry and Biomedicine Innovation Cen…. Hauptthemen laut MEDLINE: Immunotherapy, Metal-Organic Frameworks, Membrane Proteins, Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundamental Research Funds for the Central Universities, State Key Laboratory of Analytical Chemistry for Life Science, Natural Science Foundation of Jiangsu Province.
Abstract (Originalsprache)
Chemo‐metalloimmunotherapy is emerging as a promising strategy for cancer treatment by integrating chemotherapy‐induced immunogenicity with metal ion‐mediated immune activation. However, its efficacy is hampered by chemoresistance and immune escape driven by PD‐L1 upregulation. Here, a multifunctional manganese‐based metal‐organic framework nanoplatform (Mn‐CDDP‐dBET6@CM) is reported that integrates metalloimmunotherapy, chemotherapy, and Proteolysis‐targeting chimera (PROTAC) ‐mediated epigenetic modulation for enhanced cancer treatment. This system co‐delivers Mn 2+ to activate the stimulator of interferon genes (STING) pathway, cisplatin (CDDP) to induce nucleus DNA damage, and the bromodomain‐containing protein 4 (BRD4) ‐targeting PROTAC dBET6 to promote mitochondrial DNA release and suppress PD‐L1‐mediated immune evasion. Coated with tumor cell membranes for homologous targeting and immune evasion, Mn‐CDDP‐dBET6@CM effectively induces cellular senescence, robust innate and adaptive immune activation, and tumor microenvironment remodeling. In vitro and in vivo studies demonstrate potent tumor growth inhibition, enhance dendritic cell maturation, and increase cytotoxic T cell infiltration. This nanoplatform offers a promising strategy to overcome chemoresistance and immunosuppression, providing a versatile approach for next‐generation chemo‐metalloimmunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Analytical Chemistry for Life Science, School of Chemistry and Chemical Engineering, Chemistry and Biomedicine Innovation Center (ChemBIC), Nanjing University, Nanjing, 210023, China.
ORCID-Profile: Jingjing Zhang
Förderung
- Fundamental Research Funds for the Central Universities
- State Key Laboratory of Analytical Chemistry for Life Science
- Natural Science Foundation of Jiangsu Province
- National Natural Science Foundation of China
Zitieren
APA
Chen, Z., Feng, Z., Wang, S., & Zhang, J. (2026). Engineering Metal‐Organic‐Framework‐Based STING Nanoagonists for PROTAC‐Enhanced Cancer Chemo‐Metalloimmunotherapy. Advanced Science, 13(2). https://doi.org/10.1002/advs.202515006
Vancouver
Chen Z, Feng Z, Wang S, Zhang J. Engineering Metal‐Organic‐Framework‐Based STING Nanoagonists for PROTAC‐Enhanced Cancer Chemo‐Metalloimmunotherapy. Advanced Science. 2026;13(2). doi:10.1002/advs.202515006
BibTeX
@article{Chen2026,
author = {Chen, Zhenzhen and Feng, Zhe and Wang, Siyuan and Zhang, Jingjing},
title = {Engineering Metal‐Organic‐Framework‐Based STING Nanoagonists for PROTAC‐Enhanced Cancer Chemo‐Metalloimmunotherapy},
journal = {Advanced Science},
year = {2026},
volume = {13},
number = {2},
doi = {10.1002/advs.202515006}
}
EUVIMED